ASCO 2020：11项中国研究入选口头年度报告，17项Poster年度报告

受全球取而代之冠疫情负面影响，原定于5同年29日~6同年2日在明尼阿波利斯举办地的美国临床研究课题研究课题会（ASCO）讨论会今年将首次以新线上形式举办，这是目前最大规模的新线上盛会。今天，开会的概述题目公布，一共103个sessions，中的国一共计11项研究课题被选为口头报告，17项被选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或莱切替尼加卡培他临海运用于HER2+冠心病乳腺恶性肿瘤（PHOEBE）：一项III期随机检验。

交响乐：冠心病乳腺恶性肿瘤

编者：北京协和医学院所医院徐兵河任教、马飞任教，复旦大学附属机构所医院胡夕春任教等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三特性性乳腺恶性肿瘤标准规范治疗法后卡培他临海维持节拍治疗的III期检验（SYSUCC-001）。

交响乐：乳腺恶性肿瘤—均匀分布/周边/专用治疗法

编者：中的山大学环境保护中的心王树森任教等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用冠心病脑的表型特性来计算小肠中的重复DNA测定的概率: 取而代之基本功能牵制杨家对手

交响乐：取而代之基本功能彻底解决杨家问题

编者：刘美芹 刘德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对里拉拉非尼作为中后期肾脏蛋白质恶性肿瘤的前沿治疗法：一项对外开放标记、随机、多中的心II/III期检验。

交响乐：呼吸道恶性肿瘤—肠胃十二指肠、恶性肿瘤变和肾脏胆

编者：四川大学特罗斯季亚涅齐所医院毕锋任教、当权者解放军朝阳所医院秦叔逵任教等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国中后期肾脏恶性肿瘤症状阿帕替尼二新线治疗法：一项随机、安慰剂比对、随机对照III期研究课题

交响乐：呼吸道恶性肿瘤—肠胃十二指肠、恶性肿瘤变和肾脏胆

编者：当权者解放军朝阳所医院秦叔逵任教、四川大学特罗斯季亚涅齐所医院刘秋任教等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期住院性卵巢恶性肿瘤二次蛋白质减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

为题：医学恶性肿瘤症

编者：复旦大学附属机构中的山所医院臧荣余任教等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶性肿瘤根治性乳腺手术后专用治疗法中的的序贯放治疗对比单独PET或定时放治疗（STARS研究课题）：一项随机、比对、对外开放标记的III期检验。

开会：医学恶性肿瘤症

编者：中的山大学环境保护中的心黄鹤任教、刘继红任教等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专用吉非替尼对比治疗运用于可切除的EGFR突变的N1-N2期NSCLC-随机III期临床研究课题检验的终究某种程度猎食分析方法。

为题：肺恶性肿瘤—非小蛋白质均匀分布-周边/小蛋白质/其他面部

编者：广东省当权者所医院吴一龙任教等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变计分散非小蛋白质肺恶性肿瘤症状前沿组氨酸激酶药物一共同或不一共同积极前新线均匀分布PET：III期对外开放标记临床研究课题随机检验（SINDAS）的中的期结果（NCT02893332）。

为题：肺恶性肿瘤-非小蛋白质分散

编者：泸州当权者所医院曾铭任教等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性丧命-1（PD-1）的人源化IgG4单克隆抗体一共同阿昔替尼运用于冠心病皮肤前列腺癌症状的Ib期研究课题的总猎食期和生物圣万分析方法。

为题：前列腺癌/皮肤恶性肿瘤

编者：北京大学所医院郭军、盛锡楠任教等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：通用CAR-T蛋白质首次药剂检验治疗法住院/难治性T蛋白质急性淋巴蛋白质白血病（r/r T-ALL）的实用性和。开会：开发设计中的的治疗法关键技术-免疫治疗法。编者：王欣欣等概述：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中后期十二指肠结节蛋白质恶性肿瘤症状中的的领域：一项随机的对外开放标记II期检验（ORIENT-2）。开会：呼吸道恶性肿瘤-肠胃十二指肠恶性肿瘤、恶性肿瘤变恶性肿瘤和肾脏胆道恶性肿瘤编者：徐建明任教等概述：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白质对质母蛋白质瘤的根除性治疗法开会：中的枢神经系统编者：代红久、孙斌、杨东、徐晖、顾晶晶、魏佳、姚旭东概述：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复缺点症状中的的领域开会：开发设计中的的治疗法学-免疫治疗法编者：沈琳任教等概述：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法住院/难治性ACUTE淋巴蛋白质白血病/霍奇金的首例药剂临床研究课题检验开会: 开发设计性治疗法学-免疫治疗法编者简介：张明志，板桥乡等概述：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酰（T）一共同应运用于中后期对等瘤症状的Ib期研究课题开会：发展性治疗法学；还有分子抑制剂药物和免疫学编者：龚继芳，沈琳任教等概述：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin一共同糖类和nedaplatin治疗法住院性或冠心病十二指肠结节蛋白质恶性肿瘤（ESCC）症状的II期研究课题。开会：呼吸道恶性肿瘤-肠胃十二指肠、恶性肿瘤变和肾脏胆道恶性肿瘤的研究课题编者：王志强于，刘玉红，王德申，王凤华，任超，谭琼 王志强于、刘玉红、王德深、王凤华、任超、谭琼概述：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开会：呼吸道恶性肿瘤-肠胃十二指肠恶性肿瘤、恶性肿瘤变恶性肿瘤和肾脏肺恶性肿瘤的二新线治疗法编者：宋艳等概述：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种粪便外体马蹄形RNA确定性运用于初始切除时测定高等级恶性肿瘤的粪便外体马蹄形RNA确定性：一项多中的心的回顾性研究课题开会：泌尿生殖系统恶性肿瘤症；还有-恶性肿瘤、睾丸恶性肿瘤和恶性肿瘤编者简介：Liaoyuan Li等概述：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布中后期宫颈恶性肿瘤并作治疗后的专用治疗开会: 医学恶性肿瘤症编者简介： 刘珉珉等概述：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法肩胛骨髓质性恶性肿瘤的一致性：基于ALTER01031检验的分析方法。会福州话：头颈部编者：天津市所医院高明任教概述：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼治疗法后症状结局的负面影响: ALTER01031的亚组分析方法开会：头颈部编者：天津市所医院高明任教概述：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法计算I-IIIA期非小蛋白质肺恶性肿瘤（NSCLC）症状术后住院: GASTO1035和GASTO1018的结果开会：肺恶性肿瘤-非小蛋白质均匀分布-周边性/小蛋白质/小蛋白质/其他胸科恶性肿瘤症编者：Si-Yu Wang等概述：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肺恶性肿瘤（NSCLC）中的EGFR组氨酸激酶药物的取而代之型耐药机制开会:肺恶性肿瘤-非小蛋白质冠心病肺恶性肿瘤编者简介：姚昕，金结缘，满宇，欧西厢记，梅氏，薛武，杨少，范敏 姚昕、金结缘、满宇、欧西厢记、梅氏、薛武、杨绍、范敏概述：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验中的中后期前列腺癌总猎食的替代终点开会：前列腺癌/皮肤恶性肿瘤编者：聂润聪，袁书强于，刘元芳，陈英波，周志伟 聂润聪、袁书强于、刘元芳、陈英波、周志伟概述：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法住院或冠心病原发性恶性肩胛骨症状的II期研究课题开会： 畸形编者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶概述：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 全面性称赞安罗替尼在中后期畸形症状多新线治疗法中的的实用性和。开会：畸形编者：姚伟涛，王家强于，张瑞，王欣，杜取而代之辉，田志浩，牛晓颖 姚伟涛、王家强于、张瑞、王鑫、杜鑫辉、田志超、牛晓英概述：11526广告：414